UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

Breast cancer research and treatment, 2016-12, Vol.160 (3), p.439-446

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

Expert opinion on therapeutic targets, 2012-01, Vol.16 (1), p.103-119

2012

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer

International journal of molecular sciences, 2023-04, Vol.24 (8), p.6945

2023

Link zum Volltext

Verfügbarkeit prüfen

A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients

Clinical cancer research, 2015-03, Vol.21 (5), p.1207-1214

2015

Link zum Volltext

Verfügbarkeit prüfen

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

Current cancer drug targets, 2015-10, Vol.15 (8), p.665

2015

Link zum Volltext

Verfügbarkeit prüfen

The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors

Endocrine reviews, 2010-08, Vol.31 (4), p.578-599

2010

Link zum Volltext

Verfügbarkeit prüfen

MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype

Endocrine-related cancer, 2010-03, Vol.17 (1), p.F51-F75

2010

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers

Current pharmaceutical design, 2013-02, Vol.19 (5), p.864

2013

Link zum Volltext

Verfügbarkeit prüfen

DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes

The oncologist (Dayton, Ohio), 2013, Vol.18 (10), p.1063-1073

2013

Link zum Volltext

Verfügbarkeit prüfen

Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer

International journal of molecular sciences, 2017-01, Vol.18 (1), p.194-194

2017

Link zum Volltext

Verfügbarkeit prüfen

Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer

Cytokine (Philadelphia, Pa.), 2012-08, Vol.59 (2), p.218-222

2012

Link zum Volltext

Verfügbarkeit prüfen

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Breast cancer research : BCR, 2013-09, Vol.15 (5), p.R86-R86, Article R86

2013

Link zum Volltext

Verfügbarkeit prüfen

Missense Mutation in the Transcription Factor NKX2–5: A Novel Molecular Event in the Pathogenesis of Thyroid Dysgenesis

The journal of clinical endocrinology and metabolism, 2006-04, Vol.91 (4), p.1428-1433

2006

Link zum Volltext

Verfügbarkeit prüfen

Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma

Human pathology, 2009-06, Vol.40 (6), p.827-833

2009

Link zum Volltext

Verfügbarkeit prüfen

Role of inflammation in obesity-related breast cancer

Current opinion in pharmacology, 2016-12, Vol.31, p.114-122

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting microRNAs as key modulators of tumor immune response

Journal of experimental & clinical cancer research, 2016-06, Vol.35 (1), p.103-103, Article 103

2016

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer assessment tools and optimizing adjuvant therapy

Nature reviews. Clinical oncology, 2010-12, Vol.7 (12), p.725-732

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Journal of thoracic oncology, 2022-01, Vol.17 (1), p.103-115

2022

Link zum Volltext

Verfügbarkeit prüfen

Progress in nonviral gene therapy for breast cancer and what comes next?

Expert opinion on biological therapy, 2017-05, Vol.17 (5), p.595-611

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-02-04: Immune Signatures Display Subtype-Specific Activation in Breast Cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P5-P5-02-04

2023

Link zum Volltext

Verfügbarkeit prüfen

Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities--report of a case and literature review

TheScientificWorld, 2010-01, Vol.10, p.126-134

2010

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Nature reviews. Clinical oncology, 2013-07, Vol.10 (7), p.377-389

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1108-TPS1108

2022

Link zum Volltext

Verfügbarkeit prüfen

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4), p.927-939

2016

Link zum Volltext

Verfügbarkeit prüfen

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

Breast cancer research : BCR, 2016-12, Vol.18 (1), p.121-121, Article 121

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 79

Suche als RSS-Feed

Aktive Filter

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Englisch
(79)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(51)
Science & Technology
(51)
Humans
(49)
Oncology
(31)
Female
(27)
Breast Cancer
(20)
Breast Neoplasms - Genetics
(11)
Breast Neoplasms - Pathology
(11)
Endocrinology & Metabolism
(11)
Adult
(9)
Breast Neoplasms - Drug Therapy
(9)
Gene Expression Regulation, Neoplastic
(9)
Health Aspects
(9)
Prognosis
(9)
Animals
(8)
Micrornas - Genetics
(8)
Biological And Medical Sciences
(7)
Cell Line, Tumor
(7)
Endocrinopathies
(7)
Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer

A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors

MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype

Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers

DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes

Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer

Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Missense Mutation in the Transcription Factor NKX2–5: A Novel Molecular Event in the Pathogenesis of Thyroid Dysgenesis

Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma

Role of inflammation in obesity-related breast cancer

Targeting microRNAs as key modulators of tumor immune response

Breast cancer assessment tools and optimizing adjuvant therapy

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Progress in nonviral gene therapy for breast cancer and what comes next?

Abstract P5-02-04: Immune Signatures Display Subtype-Specific Activation in Breast Cancer

Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities--report of a case and literature review

Circulating tumour cells and cell-free DNA as tools for managing breast cancer

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

Aktive Filter

Suchergebnisse filtern